BeiGene announced that its product, Brukinsa®, has received accelerated approval from the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL) who have received at least two lines of prior systemic therapy (including Bruton's tyrosine kinase (BTK) inhibitors).
